Potential Role of Seven Proteomics Tissue Biomarkers for Diagnosis and Prognosis of Prostate Cancer in Urine
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Selection of Candidates
2.2. Patient Data and Samples
2.3. Quantitative Measurement of Candidate Proteins in Urine
2.4. Statistical Analysis
3. Results
3.1. Meta-Analysis of PCa Tissue Proteomics Studies
3.2. Diagnostic Sensitivity and Specificity in PCa Detection
3.3. Diagnostic Sensitivity and Specificity in PCa Progression
3.4. Correlation between Tested Biomarkers and Clinical Parameters
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Loeb, S.; Bjurlin, M.A.; Nicholson, J.; Tammela, T.L.; Penson, D.F.; Carter, H.B.; Carroll, P.; Etzioni, R. Overdiagnosis and overtreatment of prostate cancer. Eur. Urol. 2014, 65, 1046–1055. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Potosky, A.L.; Feuer, E.J.; Levin, D.L. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol. Rev. 2001, 23, 181–186. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mottet, N.; Bellmunt, J.; Bolla, M.; Briers, E.; Cumberbatch, M.G.; De Santis, M.; Fossati, N.; Gross, T.; Henry, A.M.; Joniau, S.; et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur. Urol. 2017, 71, 618–629. [Google Scholar] [CrossRef]
- Thompson, I.M.; Pauler, D.K.; Goodman, P.J.; Tangen, C.M.; Lucia, M.S.; Parnes, H.L.; Minasian, L.M.; Ford, L.G.; Lippman, S.M.; Crawford, E.D.; et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N. Engl. J. Med. 2004, 350, 2239–2246. [Google Scholar] [CrossRef] [Green Version]
- Tonry, C.; Finn, S.; Armstrong, J.; Pennington, S.R. Clinical proteomics for prostate cancer: Understanding prostate cancer pathology and protein biomarkers for improved disease management. Clin. Proteom. 2020, 17, 41. [Google Scholar] [CrossRef]
- Cucchiara, V.; Cooperberg, M.R.; Dall’Era, M.; Lin, D.W.; Montorsi, F.; Schalken, J.A.; Evans, C.P. Genomic Markers in Prostate Cancer Decision Making. Eur. Urol. 2018, 73, 572–582. [Google Scholar] [CrossRef]
- Press, B.; Schulster, M.; Bjurlin, M.A. Differentiating Molecular Risk Assessments for Prostate Cancer. Rev. Urol. 2018, 20, 12–18. [Google Scholar] [CrossRef]
- Davalieva, K.; Polenakovic, M. Proteomics in diagnosis of prostate cancer. Pril. Makedon. Akad. Na Nauk. Umet. Oddel. Za Med. Nauk. 2015, 36, 5–36. [Google Scholar]
- Latosinska, A.; Frantzi, M.; Merseburger, A.S.; Mischak, H. Promise and Implementation of Proteomic Prostate Cancer Biomarkers. Diagnostics 2018, 8, 57. [Google Scholar] [CrossRef] [Green Version]
- Digre, A.; Lindskog, C. The Human Protein Atlas-Spatial localization of the human proteome in health and disease. Protein Sci. 2021, 30, 218–233. [Google Scholar] [CrossRef] [PubMed]
- Keshava Prasad, T.S.; Goel, R.; Kandasamy, K.; Keerthikumar, S.; Kumar, S.; Mathivanan, S.; Telikicherla, D.; Raju, R.; Shafreen, B.; Venugopal, A.; et al. Human Protein Reference Database—2009 update. Nucleic Acids Res. 2009, 37, D767–D772. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Waterhouse, R.L., Jr.; Van Neste, L.; Moses, K.A.; Barnswell, C.; Silberstein, J.L.; Jalkut, M.; Tutrone, R.; Sylora, J.; Anglade, R.; Murdock, M.; et al. Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men. Urology 2019, 128, 62–65. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brooks, M.A.; Thomas, L.; Magi-Galluzzi, C.; Li, J.; Crager, M.R.; Lu, R.; Abran, J.; Aboushwareb, T.; Klein, E.A. GPS Assay Association with Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer-Specific Mortality. JCO Precis. Oncol. 2021, 5, 442–449. [Google Scholar] [CrossRef]
- Badani, K.; Thompson, D.J.; Buerki, C.; Davicioni, E.; Garrison, J.; Ghadessi, M.; Mitra, A.P.; Wood, P.J.; Hornberger, J. Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: A report from the DECIDE study group. Oncotarget 2013, 4, 600–609. [Google Scholar] [CrossRef] [Green Version]
- Addinsoft. XLSTAT Statistical and Data Analysis Solution; Addinsoft: New York, NY, USA, 2019; Available online: https://www.xlstat.com (accessed on 1 December 2022).
- Faul, F.; Erdfelder, E.; Lang, A.G.; Buchner, A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 2007, 39, 175–191. [Google Scholar] [CrossRef]
- Alaiya, A.A.; Al-Mohanna, M.; Aslam, M.; Shinwari, Z.; Al-Mansouri, L.; Al-Rodayan, M.; Al-Eid, M.; Ahmad, I.; Hanash, K.; Tulbah, A.; et al. Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma. Int. J. Oncol. 2011, 38, 1047–1057. [Google Scholar] [CrossRef]
- Blume-Jensen, P.; Berman, D.M.; Rimm, D.L.; Shipitsin, M.; Putzi, M.; Nifong, T.P.; Small, C.; Choudhury, S.; Capela, T.; Coupal, L.; et al. Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer. Clin. Cancer Res. 2015, 21, 2591–2600. [Google Scholar] [CrossRef] [Green Version]
- Chen, J.; Xi, J.; Tian, Y.; Bova, G.S.; Zhang, H. Identification, prioritization, and evaluation of glycoproteins for aggressive prostate cancer using quantitative glycoproteomics and antibody-based assays on tissue specimens. Proteomics 2013, 13, 2268–2277. [Google Scholar] [CrossRef] [Green Version]
- Cheung, P.K.; Woolcock, B.; Adomat, H.; Sutcliffe, M.; Bainbridge, T.C.; Jones, E.C.; Webber, D.; Kinahan, T.; Sadar, M.; Gleave, M.E.; et al. Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Res. 2004, 64, 5929–5933. [Google Scholar] [CrossRef] [Green Version]
- Davalieva, K.; Kostovska, I.M.; Kiprijanovska, S.; Markoska, K.; Kubelka-Sabit, K.; Filipovski, V.; Stavridis, S.; Stankov, O.; Komina, S.; Petrusevska, G.; et al. Proteomics analysis of malignant and benign prostate tissue by 2D DIGE/MS reveals new insights into proteins involved in prostate cancer. Prostate 2015, 75, 1586–1600. [Google Scholar] [CrossRef] [PubMed]
- Garbis, S.D.; Tyritzis, S.I.; Roumeliotis, T.; Zerefos, P.; Giannopoulou, E.G.; Vlahou, A.; Kossida, S.; Diaz, J.; Vourekas, S.; Tamvakopoulos, C.; et al. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. J. Proteome Res. 2008, 7, 3146–3158. [Google Scholar] [CrossRef] [PubMed]
- Glen, A.; Evans, C.A.; Gan, C.S.; Cross, S.S.; Hamdy, F.C.; Gibbins, J.; Lippitt, J.; Eaton, C.L.; Noirel, J.; Wright, P.C.; et al. Eight-plex iTRAQ analysis of variant metastatic human prostate cancer cells identifies candidate biomarkers of progression: An exploratory study. Prostate 2010, 70, 1313–1332. [Google Scholar] [CrossRef]
- Glen, A.; Gan, C.S.; Hamdy, F.C.; Eaton, C.L.; Cross, S.S.; Catto, J.W.; Wright, P.C.; Rehman, I. iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression. J. Proteome Res. 2008, 7, 897–907. [Google Scholar] [CrossRef] [PubMed]
- Han, Z.D.; Zhang, Y.Q.; He, H.C.; Dai, Q.S.; Qin, G.Q.; Chen, J.H.; Cai, C.; Fu, X.; Bi, X.C.; Zhu, J.G.; et al. Identification of novel serological tumor markers for human prostate cancer using integrative transcriptome and proteome analysis. Med. Oncol. 2012, 29, 2877–2888. [Google Scholar] [CrossRef] [PubMed]
- Iglesias-Gato, D.; Wikstrom, P.; Tyanova, S.; Lavallee, C.; Thysell, E.; Carlsson, J.; Hagglof, C.; Cox, J.; Andren, O.; Stattin, P.; et al. The Proteome of Primary Prostate Cancer. Eur. Urol. 2016, 69, 942–952. [Google Scholar] [CrossRef] [PubMed]
- Jiang, F.N.; He, H.C.; Zhang, Y.Q.; Yang, D.L.; Huang, J.H.; Zhu, Y.X.; Mo, R.J.; Chen, G.; Yang, S.B.; Chen, Y.R.; et al. An integrative proteomics and interaction network-based classifier for prostate cancer diagnosis. PLoS ONE 2013, 8, e63941. [Google Scholar] [CrossRef] [Green Version]
- Latonen, L.; Afyounian, E.; Jylha, A.; Nattinen, J.; Aapola, U.; Annala, M.; Kivinummi, K.K.; Tammela TT, L.; Beuerman, R.W.; Uusitalo, H.; et al. Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. Nat. Commun. 2018, 9, 1176. [Google Scholar] [CrossRef] [Green Version]
- Lin, J.F.; Xu, J.; Tian, H.Y.; Gao, X.; Chen, Q.X.; Gu, Q.; Xu, G.J.; Song, J.D.; Zhao, F.K. Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis. Int. J. Cancer 2007, 121, 2596–2605. [Google Scholar] [CrossRef]
- Liu, A.Y.; Zhang, H.; Sorensen, C.M.; Diamond, D.L. Analysis of prostate cancer by proteomics using tissue specimens. J. Urol. 2005, 173, 73–78. [Google Scholar] [CrossRef]
- Liu, Y.; Chen, J.; Sethi, A.; Li, Q.K.; Chen, L.; Collins, B.; Gillet, L.C.; Wollscheid, B.; Zhang, H.; Aebersold, R. Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-acylethanolamine acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness. Mol. Cell. Proteom. MCP 2014, 13, 1753–1768. [Google Scholar] [CrossRef] [PubMed]
- Meehan, K.L.; Holland, J.W.; Dawkins, H.J. Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 2002, 50, 54–63. [Google Scholar] [CrossRef] [PubMed]
- Pang, J.; Liu, W.P.; Liu, X.P.; Li, L.Y.; Fang, Y.Q.; Sun, Q.P.; Liu, S.J.; Li, M.T.; Su, Z.L.; Gao, X. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis. J. Proteome Res. 2010, 9, 216–226. [Google Scholar] [CrossRef] [PubMed]
- Saraon, P.; Cretu, D.; Musrap, N.; Karagiannis, G.S.; Batruch, I.; Drabovich, A.P.; van der Kwast, T.; Mizokami, A.; Morrissey, C.; Jarvi, K.; et al. Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression. Mol. Cell. Proteom. MCP 2013, 12, 1589–1601. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shipitsin, M.; Small, C.; Choudhury, S.; Giladi, E.; Friedlander, S.; Nardone, J.; Hussain, S.; Hurley, A.D.; Ernst, C.; Huang, Y.E.; et al. Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br. J. Cancer 2014, 111, 1201–1212. [Google Scholar] [CrossRef]
- Skvortsov, S.; Schafer, G.; Stasyk, T.; Fuchsberger, C.; Bonn, G.K.; Bartsch, G.; Klocker, H.; Huber, L.A. Proteomics profiling of microdissected low- and high-grade prostate tumors identifies Lamin A as a discriminatory biomarker. J. Proteome Res. 2011, 10, 259–268. [Google Scholar] [CrossRef]
- Sun, C.; Song, C.; Ma, Z.; Xu, K.; Zhang, Y.; Jin, H.; Tong, S.; Ding, W.; Xia, G.; Ding, Q. Periostin identified as a potential biomarker of prostate cancer by iTRAQ-proteomics analysis of prostate biopsy. Proteome Sci. 2011, 9, 22. [Google Scholar] [CrossRef] [Green Version]
- Ummanni, R.; Junker, H.; Zimmermann, U.; Venz, S.; Teller, S.; Giebel, J.; Scharf, C.; Woenckhaus, C.; Dombrowski, F.; Walther, R. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer. Cancer Lett. 2008, 266, 171–185. [Google Scholar] [CrossRef]
- Ummanni, R.; Mundt, F.; Pospisil, H.; Venz, S.; Scharf, C.; Barett, C.; Falth, M.; Kollermann, J.; Walther, R.; Schlomm, T.; et al. Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform. PLoS ONE 2011, 6, e16833. [Google Scholar] [CrossRef] [Green Version]
- Zheng, Y.; Xu, Y.; Ye, B.; Lei, J.; Weinstein, M.H.; O’Leary, M.P.; Richie, J.P.; Mok, S.C.; Liu, B.C. Prostate carcinoma tissue proteomics for biomarker discovery. Cancer 2003, 98, 2576–2582. [Google Scholar] [CrossRef]
- Bhowmick, N.A.; Moses, H.L. Tumor-stroma interactions. Curr. Opin. Genet. Dev. 2005, 15, 97–101. [Google Scholar] [CrossRef] [PubMed]
- Cappello, P.; Principe, M.; Bulfamante, S.; Novelli, F. Alpha-Enolase (ENO1), a potential target in novel immunotherapies. Front. Biosci. 2017, 22, 944–959. [Google Scholar] [CrossRef]
- Huang, C.K.; Sun, Y.; Lv, L.; Ping, Y. ENO1 and Cancer. Mol. Ther. Oncolytics 2022, 24, 288–298. [Google Scholar] [CrossRef] [PubMed]
- Clucas, J.; Valderrama, F. ERM proteins in cancer progression. J. Cell Sci. 2014, 127 Pt 2, 267–275. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Song, Y.; Ma, X.; Zhang, M.; Wang, M.; Wang, G.; Ye, Y.; Xia, W. Ezrin Mediates Invasion and Metastasis in Tumorigenesis: A Review. Front. Cell Dev. Biol. 2020, 8, 588801. [Google Scholar] [CrossRef]
- Wei, X.; Liu, X.; Tan, C.; Mo, L.; Wang, H.; Peng, X.; Deng, F.; Chen, L. Expression and Function of Zinc-alpha2-Glycoprotein. Neurosci. Bull. 2019, 35, 540–550. [Google Scholar] [CrossRef]
- Kong, B.; Michalski, C.W.; Hong, X.; Valkovskaya, N.; Rieder, S.; Abiatari, I.; Streit, S.; Erkan, M.; Esposito, I.; Friess, H.; et al. AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial transdifferentiation by inhibiting TGF-beta-mediated ERK signaling. Oncogene 2010, 29, 5146–5158. [Google Scholar] [CrossRef] [Green Version]
- Cui, J.; Li, G.; Yin, J.; Li, L.; Tan, Y.; Wei, H.; Liu, B.; Deng, L.; Tang, J.; Chen, Y.; et al. GSTP1 and cancer: Expression, methylation, polymorphisms and signaling (Review). Int. J. Oncol. 2020, 56, 867–878. [Google Scholar] [CrossRef]
- Morgan, E.; Kannan-Thulasiraman, P.; Noy, N. Involvement of Fatty Acid Binding Protein 5 and PPARbeta/delta in Prostate Cancer Cell Growth. PPAR Res. 2010, 2010, 234629. [Google Scholar] [CrossRef] [Green Version]
- Morgan, E.A.; Forootan, S.S.; Adamson, J.; Foster, C.S.; Fujii, H.; Igarashi, M.; Beesley, C.; Smith, P.H.; Ke, Y. Expression of cutaneous fatty acid-binding protein (C-FABP) in prostate cancer: Potential prognostic marker and target for tumourigenicity-suppression. Int. J. Oncol. 2008, 32, 767–775. [Google Scholar]
- Myers, J.S.; von Lersner, A.K.; Sang, Q.X. Proteomic Upregulation of Fatty Acid Synthase and Fatty Acid Binding Protein 5 and Identification of Cancer- and Race-Specific Pathway Associations in Human Prostate Cancer Tissues. J. Cancer 2016, 7, 1452–1464. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Davalieva, K.; Kiprijanovska, S.; Maleva Kostovska, I.; Stavridis, S.; Stankov, O.; Komina, S.; Petrusevska, G.; Polenakovic, M. Comparative Proteomics Analysis of Urine Reveals Down-Regulation of Acute Phase Response Signaling and LXR/RXR Activation Pathways in Prostate Cancer. Proteomes 2017, 6, 1. [Google Scholar] [CrossRef] [PubMed]
- Duijvesz, D.; Burnum-Johnson, K.E.; Gritsenko, M.A.; Hoogland, A.M.; Vredenbregt-van den Berg, M.S.; Willemsen, R.; Luider, T.; Pasa-Tolic, L.; Jenster, G. Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer. PLoS ONE 2013, 8, e82589. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rehman, I.; Azzouzi, A.R.; Catto, J.W.; Allen, S.; Cross, S.S.; Feeley, K.; Meuth, M.; Hamdy, F.C. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: A pilot study. Urology 2004, 64, 1238–1243. [Google Scholar] [CrossRef] [PubMed]
- Fujita, K.; Kume, H.; Matsuzaki, K.; Kawashima, A.; Ujike, T.; Nagahara, A.; Uemura, M.; Miyagawa, Y.; Tomonaga, T.; Nonomura, N. Proteomic analysis of urinary extracellular vesicles from high Gleason score prostate cancer. Sci. Rep. 2017, 7, 42961. [Google Scholar] [CrossRef] [Green Version]
- Dhondt, B.; Geeurickx, E.; Tulkens, J.; Van Deun, J.; Vergauwen, G.; Lippens, L.; Miinalainen, I.; Rappu, P.; Heino, J.; Ost, P.; et al. Unravelling the proteomic landscape of extracellular vesicles in prostate cancer by density-based fractionation of urine. J. Extracell. Vesicles 2020, 9, 1736935. [Google Scholar] [CrossRef]
- Pang, S.T.; Fang, X.; Valdman, A.; Norstedt, G.; Pousette, A.; Egevad, L.; Ekman, P. Expression of ezrin in prostatic intraepithelial neoplasia. Urology 2004, 63, 609–612. [Google Scholar] [CrossRef]
- Valdman, A.; Fang, X.; Pang, S.T.; Nilsson, B.; Ekman, P.; Egevad, L. Ezrin expression in prostate cancer and benign prostatic tissue. Eur. Urol. 2005, 48, 852–857. [Google Scholar] [CrossRef]
- Henshall, S.M.; Horvath, L.G.; Quinn, D.I.; Eggleton, S.A.; Grygiel, J.J.; Stricker, P.D.; Biankin, A.V.; Kench, J.G.; Sutherland, R.L. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J. Natl. Cancer Inst. 2006, 98, 1420–1424. [Google Scholar] [CrossRef] [Green Version]
- Kristensen, G.; Berg, K.D.; Toft, B.G.; Stroomberg, H.V.; Nolley, R.; Brooks, J.D.; Brasso, K.; Roder, M.A. Predictive value of AZGP1 following radical prostatectomy for prostate cancer: A cohort study and meta-analysis. J. Clin. Pathol. 2019, 72, 696–704. [Google Scholar] [CrossRef]
- Lapointe, J.; Li, C.; Higgins, J.P.; van de Rijn, M.; Bair, E.; Montgomery, K.; Ferrari, M.; Egevad, L.; Rayford, W.; Bergerheim, U.; et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl. Acad. Sci. USA 2004, 101, 811–816. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yip, P.Y.; Kench, J.G.; Rasiah, K.K.; Benito, R.P.; Lee, C.S.; Stricker, P.D.; Henshall, S.M.; Sutherland, R.L.; Horvath, L.G. Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer. Prostate 2011, 71, 1638–1645. [Google Scholar] [CrossRef] [PubMed]
- O’Hurley, G.; O’Grady, A.; Smyth, P.; Byrne, J.; O’Leary, J.J.; Sheils, O.; William, R.; Watson, G.; Kay, E.W. Evaluation of Zinc-alpha-2-Glycoprotein and Proteasome Subunit beta-Type 6 Expression in Prostate Cancer Using Tissue Microarray Technology. Appl. Immunohistochem. Mol. Morphol. 2010, 18, 512–517. [Google Scholar] [CrossRef] [PubMed]
- Rehman, I.; Evans, C.A.; Glen, A.; Cross, S.S.; Eaton, C.L.; Down, J.; Pesce, G.; Phillips, J.T.; Yen, O.S.; Thalmann, G.N.; et al. iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer. PLoS ONE 2012, 7, e30885. [Google Scholar] [CrossRef]
- Byrne, J.C.; Downes, M.R.; O’Donoghue, N.; O’Keane, C.; O’Neill, A.; Fan, Y.; Fitzpatrick, J.M.; Dunn, M.; Watson, R.W. 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. J. Proteome Res. 2009, 8, 942–957. [Google Scholar] [CrossRef]
- Katafigiotis, I.; Tyritzis, S.I.; Stravodimos, K.G.; Alamanis, C.; Pavlakis, K.; Vlahou, A.; Makridakis, M.; Katafigioti, A.; Garbis, S.D.; Constantinides, C.A. Zinc alpha2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer. BJU Int. 2012, 110 Pt B, E688–E693. [Google Scholar] [CrossRef]
- Geisler, C.; Gaisa, N.T.; Pfister, D.; Fuessel, S.; Kristiansen, G.; Braunschweig, T.; Gostek, S.; Beine, B.; Diehl, H.C.; Jackson, A.M.; et al. Identification and validation of potential new biomarkers for prostate cancer diagnosis and prognosis using 2D-DIGE and MS. BioMed Res. Int. 2015, 2015, 454256. [Google Scholar] [CrossRef]
- Latosinska, A.; Davalieva, K.; Makridakis, M.; Mullen, W.; Schanstra, J.P.; Vlahou, A.; Mischak, H.; Frantzi, M. Molecular Changes in Tissue Proteome during Prostate Cancer Development: Proof-of-Principle Investigation. Diagnostics 2020, 10, 655. [Google Scholar] [CrossRef]
Group | Diagnosis | Patients per Group | Age (Mean ± SD) | Age (Median) | PSA (Mean ± SD) | Serum PSA (Median) | Gleason Score | Histopathological Stage | Stage | ||
---|---|---|---|---|---|---|---|---|---|---|---|
T | N | M | |||||||||
Control | Benign prostate hyperplasia | 17 | 68.9 ± 6.5 | 68.0 | 8.8 ± 4.8 | 7.6 | / | / | / | / | / |
GS6 | Prostate cancer (Gleason score = 6) | 17 | 66.7 ± 5.8 | 68.0 | 9.7 ± 8.2 | 7.6 | (3 + 3) | T2-T3a | Nx-N0 | Mx | I–IIIB |
GS7 | Prostate cancer (Gleason score = 7) | 18 | 67.7 ± 4.6 | 68.5 | 15.8 ± 13.6 | 11.7 | (3 + 4) (4 + 3) | T2c-T4b | Nx-N0 | Mx | II–IIIB |
GS8 | Prostate cancer (Gleason score = 8) | 15 | 69.4 ± 7.1 | 70.0 | 28.9 ± 24.6 | 19.3 | (3 + 5) (4 + 4) | T3b-T4 | N0-N1 | Mx | III–IV |
GS9 | Prostate cancer (Gleason score = 9) | 18 | 67.7 ± 6.0 | 67.0 | 80.1 ± 72.2 | 66.5 | (4 + 5) (5 + 4) | T2b-T4 | N0-N1 | Mx | III–IV |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vujicic, I.; Rusevski, A.; Stankov, O.; Popov, Z.; Dimovski, A.; Davalieva, K. Potential Role of Seven Proteomics Tissue Biomarkers for Diagnosis and Prognosis of Prostate Cancer in Urine. Diagnostics 2022, 12, 3184. https://doi.org/10.3390/diagnostics12123184
Vujicic I, Rusevski A, Stankov O, Popov Z, Dimovski A, Davalieva K. Potential Role of Seven Proteomics Tissue Biomarkers for Diagnosis and Prognosis of Prostate Cancer in Urine. Diagnostics. 2022; 12(12):3184. https://doi.org/10.3390/diagnostics12123184
Chicago/Turabian StyleVujicic, Ivo, Aleksandar Rusevski, Oliver Stankov, Zivko Popov, Aleksandar Dimovski, and Katarina Davalieva. 2022. "Potential Role of Seven Proteomics Tissue Biomarkers for Diagnosis and Prognosis of Prostate Cancer in Urine" Diagnostics 12, no. 12: 3184. https://doi.org/10.3390/diagnostics12123184